PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma.

Doxorubicin (DOX) is one of most common anti-cancer chemotherapeutic drugs, but its clinical use is associated with dose-limiting cardiotoxicity. We have recently developed a series of PEG-oligocholic acid based telodendrimers, which can efficiently encapsulate hydrophobic drugs and self-assemble to form stable micelles in aqueous condition. In the present study, two representative telodendrimers (PEG(5k)-CA(8) and PEG(2k)-CA(4)) have been applied to prepare DOX micellar formulations for the targeted delivery of DOX to lymphoma. PEG(2k)-CA(4) micelles, compared to PEG(5k)-CA(8) micelles, were found to have higher DOX loading capacity (14.8% vs. 8.2%, w/w), superior stability in physiological condition, and more sustained release profile. Both of these DOX-loaded micelles can be efficiently internalized and release the drug in Raji lymphoma cells. DOX-loaded micelles were found to exhibit similar in vitro cytotoxic activities against both T- and B-lymphoma cells as the free DOX. The maximum tolerated dose (MTD) of DOX-loaded PEG(2k)-CA(4) micelles in mice was approximately 15 mg/kg, which was 1.5-fold higher of the MTD of free DOX. Pharmacokinetics and biodistribution studies demonstrated that both DOX-loaded micelles were able to prolong the blood retention time, preferentially accumulate and penetrate in B-cell lymphomas via the enhanced permeability and retention (EPR) effect. Finally, DOX-PEG(2k)-CA(4) micelles achieved enhanced anti-cancer efficacy and prolonged survival in Raji lymphoma bearing mice, compared to free DOX and PEGylated liposomal DOX (Doxil®) at the equivalent dose. In addition, the analysis of creatine kinase (CK) and lactate dehydrogenase (LDH) serum enzymes level indicated that DOX micellar formulations significantly reduced the cardiotoxicity associated with free DOX.

[1]  Li Wang,et al.  A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. , 2009, Biomaterials.

[2]  P. Philip,et al.  Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors , 2004, Investigational New Drugs.

[3]  E. Macewen,et al.  Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors , 1997, Cancer Chemotherapy and Pharmacology.

[4]  M. Shieh,et al.  Reversal of doxorubicin-resistance by multifunctional nanoparticles in MCF-7/ADR cells. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[5]  R. Liggins,et al.  Solubilization of hydrophobic drugs by methoxy poly(ethylene glycol)-block-polycaprolactone diblock copolymer micelles: theoretical and experimental data and correlations. , 2008, Journal of pharmaceutical sciences.

[6]  K. Lam,et al.  A novel size-tunable nanocarrier system for targeted anticancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[7]  Jun Wang,et al.  Doxorubicin-tethered responsive gold nanoparticles facilitate intracellular drug delivery for overcoming multidrug resistance in cancer cells. , 2011, ACS nano.

[8]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[9]  Yoshinobu Fukumori,et al.  Nanoparticles for cancer therapy and diagnosis , 2006 .

[10]  H. Pinedo,et al.  Doxorubicin compared with related compounds in a nude mouse model for human ovarian cancer. , 1990, European journal of cancer.

[11]  Kit S Lam,et al.  Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. , 2011, Biomaterials.

[12]  Abby M. Gonik,et al.  The passive targeting of polymeric micelles in various types and sizes of tumor models , 2010 .

[13]  Kit S Lam,et al.  Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. , 2010, Bioconjugate chemistry.

[14]  J. Fréchet,et al.  Dendrimers and dendritic polymers in drug delivery. , 2005, Drug discovery today.

[15]  O. Fodstad,et al.  Superior therapeutic efficacy of N-L-leucyl-doxorubicin versus doxorubicin in human melanoma xenografts correlates with higher tumour concentrations of free drug. , 1999, European journal of cancer.

[16]  Forrest M Kievit,et al.  Doxorubicin loaded iron oxide nanoparticles overcome multidrug resistance in cancer in vitro. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[17]  Kit S Lam,et al.  The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. , 2011, Biomaterials.

[18]  Kazunori Kataoka,et al.  Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability, controlled subcellular drug distribution, and enhanced in vivo antitumor efficacy. , 2005, Bioconjugate chemistry.

[19]  Kit S Lam,et al.  Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. , 2006, Nature chemical biology.

[20]  T. Andresen,et al.  Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. , 2005, Progress in lipid research.

[21]  B. Sikic,et al.  Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene , 1993, Pharmacotherapy.

[22]  K. Levón,et al.  Liposome-nanogel structures for future pharmaceutical applications. , 2006, Current pharmaceutical design.

[23]  Hua Ai,et al.  Micellar carriers based on block copolymers of poly(ε-caprolactone) and poly(ethylene glycol) for doxorubicin delivery , 2004 .

[24]  Hong Yuan,et al.  Synthesis and antitumor activity of doxorubicin conjugated stearic acid-g-chitosan oligosaccharide polymeric micelles. , 2009, Biomaterials.

[25]  Jinming Gao,et al.  Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Hong Yuan,et al.  Synthesis and antitumor activity of stearate-g-dextran micelles for intracellular doxorubicin delivery. , 2010, ACS nano.

[27]  Kinam Park,et al.  Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle–cell interaction , 2010, Expert opinion on drug delivery.

[28]  P. Fong,et al.  PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. , 2009, Nanomedicine : nanotechnology, biology, and medicine.

[29]  C. Ehrhardt,et al.  Liposomes as targeted drug delivery systems in the treatment of breast cancer , 2006, Journal of drug targeting.

[30]  F. Moriyasu,et al.  Pharmaceutical and Biomedical Differences between Micellar Doxorubicin (NK911) and Liposomal Doxorubicin (Doxil) , 2002, Japanese journal of cancer research : Gann.

[31]  Vladimir P Torchilin,et al.  Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. , 2004, Advanced drug delivery reviews.